section name header

Indications ⬇

IM:

REMS

Unlabeled Use:
  • Management of diarrhea associated with chemotherapy or graft-versus-host disease.
  • Gastroesophageal variceal hemorrhage.

Contraind./Precautions ⬆ ⬇

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects ⬆ ⬇

CV: edema, QT interval prolongation, atrioventricular block, bradycardia, hypertension, orthostatic hypotension, palpitations

Derm: ↑sweating, flushing

EENT: sinusitis, visual disturbances

Endo: hyperglycemia, hypoglycemia, hypothyroidism

GI: abdominal pain, cholelithiasis, diarrhea, nausea, vomiting, abdominal bloating, cholecystitis, fat malabsorption, flatulence, ILEUS, PANCREATITIS, steatorrhea, stool discoloration

GU: urinary tract infection

Local: injection-site pain

Metab: weight loss

MS: arthralgia

Neuro: headache, dizziness, drowsiness, fatigue, weakness.

Misc: ↓vitamin B12 levels

Interactions ⬆ ⬇

Drug-drug:

Availability ⬆ ⬇

(Generic available)

Route/Dosage ⬆ ⬇

Carcinoid Tumors

VIPomas

Acromegaly

Renal Impairment

Diarrhea Associated With Chemotherapy (off-label)

Diarrhea Associated With Graft-Versus-Host Disease (off-label)

Gastroesophageal Variceal Hemorrhage (off-label)

US Brand Names ⬆ ⬇

Mycapssa, SandoSTATIN, SandoSTATIN LAR Depot

Action ⬆ ⬇

  • Suppresses secretion of serotonin and gastroenterohepatic peptides.
  • Increases absorption of fluid and electrolytes from the GI tract and increases transit time.
  • Decreases levels of serotonin metabolites.
  • Also suppresses growth hormone, insulin, and glucagon.
Therapeutic effects:
  • Normalization of growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels and maintenance of these levels.
  • Control of severe flushing and diarrhea associated with metastatic carcinoid tumors and VIPomas.

Classifications ⬆ ⬇

Therapeutic Classification: antidiarrheals, hormones

Pharmacokinetics ⬆ ⬇

Absorption: IV administration results in complete bioavailability. Well absorbed following SUBQ administration and IM administration of depot form. Food ↓ rate and extent of oral absorption.

Distribution: Some distribution to extravascular tissues.

Metabolism/Excretion: Extensive hepatic metabolism; 32% excreted unchanged in urine.

Half-Life: 1.5 hr.

Canadian Brand Names ⬆ ⬇

SandoSTATIN LAR

Time/Action Profile ⬆ ⬇

(control of symptoms)

ROUTEONSETPEAKDURATION
SUBQ, IVunknownunknownup to 12 hr
IM (LAR depot)unknown2 wkup to 4 wk
POunknownunknownunknown

Patient/Family Teaching ⬆ ⬇

Pronunciation ⬆ ⬇

ok-TREE-oh-tide

Code ⬆

NDC Code